探索BRCA1与BRCA2突变类型及位置对铂敏感复发性卵巢癌患者奥拉帕利维持治疗的影响:单中心报告
本研究评估100例BRCA1/2突变铂敏感复发性卵巢癌患者接受奥拉帕利维持单药治疗的无进展生存期和总生存期。BRCA1突变者无进展生存期和总生存期均显著短于BRCA2突变者;BRCA1 RING结构域突变者无进展生存期短于DNA结合域和BRCT结构域突变者;生殖系与体细胞突变者生存无显著差异,但停药原因有显著差异。
要点
- BRCA1突变者无进展生存期14.0个月,短于BRCA2突变者的38.8个月,差异有统计学意义。
- BRCA1突变者总生存期21.8个月,短于BRCA2突变者的62.0个月,差异有统计学意义。
- BRCA1 RING结构域突变者无进展生存期12.4个月,短于DNA结合域和BRCT结构域突变者的23.0个月。
核心结论
- BRCA1和BRCA2致病性/可能致病性变异(PV)的类型和位置可为铂敏感复发性卵巢癌患者奥拉帕利维持治疗的预期生存结局提供额外信息。
研究设计与样本
- 单中心研究,评估100例在本中心接受治疗的BRCA1/2突变铂敏感复发性卵巢癌患者,分析无进展生存期和总生存期。
- 生殖系和肿瘤BRCA1/2基因分型采用Illumina下一代测序(NGS)进行。
- 试验注册号ISRCTN42408038,注册机构为ISRCTN注册库,注册日期为2015年11月24日。
主要发现
- BRCA1突变者无进展生存期14.0个月,BRCA2突变者38.8个月,差异有统计学意义(p=0.007)。
- BRCA1突变者总生存期21.8个月,BRCA2突变者62.0个月,差异有统计学意义(p=0.011)。
- 在第一次/第二次复发患者中,BRCA1 RING结构域突变者无进展生存期12.4个月,DNA结合域(DBD)和BRCT结构域突变者23.0个月,差异有统计学意义(p=0.046)。
- 生殖系与体细胞BRCA1/2突变者无进展生存期14.9个月 vs 19.3个月(p=0.316),总生存期未达到 vs 25.8个月(p=0.224),均无显著差异。
- 生殖系与体细胞BRCA1/2突变者奥拉帕利维持治疗停药原因有显著差异,主要因不良副作用。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: In patients with platinum-sensitive relapsed ovarian cancer (PSROC) harboring pathogenic/likely pathogenic variants (PV) in BRCA1 and BRCA2 genes, olaparib maintenance monotherapy (OMT) is a viable option. Our study aimed to evaluate the impact of different BRCA1/2 PV in survival outcomes and safety of OMT in BRCA1/2-mutated PSROC patients, focusing on the type and location of PV. METHODS: We assessed the outcomes of 100 BRCA1/2-mutated PSROC patients treated at our institute, analyzing progression-free survival (PFS) and overall survival (OS). Germline and tumor BRCA1/2 genotyping was conducted using Illumina's next-generation sequencing (NGS). RESULTS: PFS and OS were significantly shorter in PSROC patients with PV in BRCA1 compared to those with PV in BRCA2 (PFS:14.0 vs. 38.8 months, p = 0.007, OS: 21.8 vs. 62.0 months, p = 0.011). Notably, there was a significant difference in PFS based on the intragenic location of BRCA1 PV, with shorter PFS in patients with 1st/2nd relapse, harboring PV in BRCA1 RING domain compared to those with PV in the DNA binding domain (DBD) and BRCT domains (12.4 vs. 23.0 months, p = 0.046). No differences in PFS and OS were observed between patients with germline versus somatic BRCA1/2 PV (PFS:14.9 vs.19.3, p = 0.316, OS: not reached vs. 25.8 months; p = 0.224). However, there were significant differences in the reasons for OMT discontinuation between patients with germline and somatic BRCA1/2 PV, primarily due to adverse side effects. CONCLUSIONS: In summary, the type and location of BRCA1 and BRCA2 PV provide additional insight into the expected survival outcomes of olaparib MT in PSROC patients. TRIAL REGISTRATION NUMBER: ISRCTN42408038, Name of registry: ISRCTN registry, Date of registration: 24/11/2015.
引用
- Škof E, Stegel V, Dragoš VŠ, et al. Exploring the impact of BRCA1 and BRCA2 mutation type and location on Olaparib maintenance therapy in platinum-sensitive relapsed ovarian Cancer patients: A single center report. Gynecol Oncol. 2024. PMID: 39178525. doi:10.1016/j.ygyno.2024.08.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。